Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hansen

Showing results (1471-1480 of 1,581) with videos related to

Pageof 159
Sort By:
Cancer Discovery|February 23, 2024
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid TumorsEric Y Stutheit-Zhao, Enrique Sanz-Garcia, Zhihui Amy Liu, et al.
Plos Medicine|January 18, 2022
Effects of preconception lifestyle intervention in infertile women with obesity: The FIT-PLESE randomized controlled trialRichard S Legro, Karl R Hansen, Michael P Diamond, et al.
JAMA|January 31, 2008
Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trialAnders M Galløe, Leif Thuesen, Henning Kelbaek, et al.
Cancer|January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMsAaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
Journal of Animal Science|October 7, 2015
Technical note: Digital quantification of eye pigmentation of cattle with white facesK M Davis, T Smith, B Bolt, et al.
JAMA Oncology|April 6, 2023
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical TrialKevin J Harrington, Robert L Ferris, Maura Gillison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2023
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical TrialAbdulazeez Salawu, Ben X Wang, Ming Han, et al.
Cell Reports. Medicine|January 17, 2024
Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemiaJames C Pino, Camilo Posso, Sunil K Joshi, et al.
Fertility and Sterility|May 11, 2020
Pregnancy registry: three-year follow-up of children conceived from letrozole, clomiphene, or gonadotropinsRichard S Legro, Michael P Diamond, Christos Coutifaris, et al.
Revista De Gastroenterologia De Mexico (English)|April 17, 2018
Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resourcesS Marciano, L Haddad, S M Borzi, et al.
Pageof 159

Showing results (1471-1480 of 1,581) with videos related to

Sort By:
Pageof 159
Cancer Discovery|February 23, 2024
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid TumorsEric Y Stutheit-Zhao, Enrique Sanz-Garcia, Zhihui Amy Liu, et al.
Plos Medicine|January 18, 2022
Effects of preconception lifestyle intervention in infertile women with obesity: The FIT-PLESE randomized controlled trialRichard S Legro, Karl R Hansen, Michael P Diamond, et al.
JAMA|January 31, 2008
Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trialAnders M Galløe, Leif Thuesen, Henning Kelbaek, et al.
Cancer|January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMsAaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
Journal of Animal Science|October 7, 2015
Technical note: Digital quantification of eye pigmentation of cattle with white facesK M Davis, T Smith, B Bolt, et al.
JAMA Oncology|April 6, 2023
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical TrialKevin J Harrington, Robert L Ferris, Maura Gillison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2023
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical TrialAbdulazeez Salawu, Ben X Wang, Ming Han, et al.
Cell Reports. Medicine|January 17, 2024
Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemiaJames C Pino, Camilo Posso, Sunil K Joshi, et al.
Fertility and Sterility|May 11, 2020
Pregnancy registry: three-year follow-up of children conceived from letrozole, clomiphene, or gonadotropinsRichard S Legro, Michael P Diamond, Christos Coutifaris, et al.
Revista De Gastroenterologia De Mexico (English)|April 17, 2018
Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resourcesS Marciano, L Haddad, S M Borzi, et al.
Pageof 159